All In Biotech

Drug Trial Radar · NCT05099770

Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

A Phase 3 Randomized Controlled Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 2 Diabetes and Chronic Kidney Disease (REGEN-006)

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 685 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

685

Planned (sponsor's estimate)

Start

Jan 5, 2022

Primary completion

Dec 2029

Study completion Dec 2029

Sponsor

Lead sponsor
ProkidneyIndustry
Sponsor type
Industry
First posted
Oct 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of up to 2 REACT/rilparencel injections in participants with T2DM and CKD.

Conditions

  • Type 2 Diabetes Mellitus
  • Chronic Kidney Diseases

Interventions

  • Renal Autologous Cell Therapy (REACT/ rilparencel)Biological

    Participants will have a kidney biopsy followed approximately12 weeks later with a rilparencel injection into the biopsied kidney, then, approximately 12 weeks later a rilparencel injection into their contralateral kidney.

  • Sham ComparatorProcedure

    Participants will have sham procedures that simulate real biopsy and injection procedure. No tissue is taken during biopsy and nothing is injected into kidney. The 2 injection/ sham procedures will occur approximately 12 weeks apart.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Surrogate / Intermediate Efficacy Endpoint -eGFR SlopeTime frame: 18 months after the 135th participant receives their first injection / sham.
  2. Clinical EndpointTime frame: From date of first injection until the date of first event: 40% reduction in eGFR, eGFR < 15 mL/min/1.73m² and/or chronic dialysis, and or renal transplant or date of renal or cardiovascular death, whichever came first, assessed up to 94 months.

Locations

88 sites in 4 countries. Site status is shown where the registry gives one.

  • Nephrology Consultants

    Huntsville, Alabama

  • University of Arizona

    Tucson, Arizona

  • Amicis Research Center

    Beverly Hills, California

  • Kidney Consultants Medical Group

    Granada Hills, California

  • IMD Clinical Trials

    Huntington Park, California

  • Advanced Medical Research, LLC

    Lakewood, California

  • Medicine and Nephrology Associates

    Los Alamitos, California

  • Academic Medical Research Institute

    Los Angeles, California

  • Southern California Hospital

    Los Angeles, California

  • Allameh Medical Corporation

    Mission Viejo, California

  • Golden Pacific Nephrology Medical Clinic Inc

    Monterey Park, California

  • Northridge Kidney Care Center

    Northridge, California

  • Valley Renal Medical Group

    Northridge, California

  • Valley Clinical Trials

    Northridge, California

  • Integrity Medical Discovery

    Pico Rivera, California

  • National Institute of Clinical Research

    Pomona, California

  • Nephrology Associates Medical Group

    Riverside, California

  • UC Davis Medical Group GI Unit

    Sacramento, California

  • North America Research Institute

    San Dimas, California

  • Henry Mayo Newhall Hospital

    Valencia, California

  • Nephrology Associates PA

    Newark, Delaware

  • West Broward Research Institute

    Coral Springs, Florida

  • Florida Kidney Physicians

    Fort Lauderdale, Florida

  • South Fort Lauderdale Nephrology

    Fort Lauderdale, Florida

  • University of Florida

    Gainesville, Florida

  • Mayo Clinic

    Jacksonville, Florida

  • Ethos Palm Beach

    Loxahatchee Groves, Florida

  • Global Clinix, LLC

    Miami, Florida

  • Professional Research Center, Inc.

    Miami, Florida

  • New Phase Clinical Trials

    Miami Beach, Florida

  • Infigo Clinical Research

    Sanford, Florida

  • Genesis Clinical Research

    Tampa, Florida

  • American Clinical Trials

    Acworth, Georgia

  • Wellstar Health System

    Augusta, Georgia

  • Boise Kidney and Hypertension PLLC

    Boise, Idaho

  • Care Institute

    Chubbuck, Idaho

  • Insight Hospital & Medical Center Chicago

    Chicago, Illinois

  • The University of Chicago Medical Center

    Chicago, Illinois

  • Indiana Nephrology

    Fishers, Indiana

  • Fresenius Kidney Care Mishawaka

    Mishawaka, Indiana

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.